rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).
|
25305506 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a literature review of five commonly requested off-label IHC predictive biomarkers in gastrointestinal tract (GIT) malignancies: HER2, mismatch repair (MMR), PD-L1, BRAF V600E and ROS1.
|
31221175 |
2019 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43).
|
26720421 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Verteporfin is highly effective as concentrations of verteporfin that do not impact tumor formation restore BRAF inhibitor suppression of tumor formation, suggesting that co-treatment with agents that inhibit YAP1 and BRAF(V600E) may be a viable therapy for cancer stem cell-derived BRAF inhibitor-resistant melanoma.
|
29299145 |
2017 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using patient-derived (V600E)BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo.
|
27617932 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two patients with treatment-refractory high-grade colorectal neuroendocrine tumors harboring BRAF(V600E) exhibited rapid and durable response to combined BRAF-MEK inhibition, providing the first clinical evidence of efficacy in this aggressive tumor type.Cancer Discov; 6(6); 594-600.
|
27048246 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease.
|
28834810 |
2017 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Transgenic induction of BRAF(V600E)in the thyroid gland results in cancers resembling human papillary thyroid cancers.
|
21249150 |
2011 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the association of BRAF(V600E) mutation with US features of thyroid nodules in predicting the malignancy of thyroid nodules in Korean patients.
|
21707687 |
2011 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thyroid-specific deletion of the Gsα gene in LSL-Braf(V600E)/TPO-Cre/Gnas-E1(fl/fl) mice also resulted in an attenuated cancer phenotype, indicating that the cooperation of TshR with oncogenic Braf is mediated in part by cAMP signaling.
|
21220306 |
2011 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for thyroid cancer if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three patients with (131)I-negative and BRAF V6</span>00E-positive recurrent cancers deceased during follow-up.
|
20647301 |
2010 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study demonstrates the activating BRAF mutation (V600E), which is found in multiple human cancers, is a driver of canine InvTCC, and highlights a urine-based test for quick diagnosis.
|
25767210 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This combinatorial effect was recapitulated in human melanoma-derived cell lines and was restricted to cancers bearing a BRAF(V600E) mutation.
|
25358764 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest additive, combinatorial activity between radiation and PLX4720 in cancers carrying BRAF V600E mutations.
|
23354848 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, in cases of indeterminate FNA with unclassifiable atypical cells BRAF (V600E) mutated, the possibility of a localization of hystiocytosis or a secondary thyroid malignancy should be taken into account.
|
26782803 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The therapeutic significance of this inhibition in cancer cells was shown while unraveling a novel mechanism of resistance to B-RAF(V600E/K) inhibitors.
|
23651636 |
2013 |